Ted Ashburn, Oncorus president and CEO

On­corus plots ear­ly-stage plant in Boston area as it walks I-O can­di­date through the clin­ic

Buoyed by what it called a suc­cess­ful 2020, Mass­a­chu­setts-based On­corus has snared a lease in the Boston area to lock down a man­u­fac­tur­ing site for its clin­i­cal-stage on­col­o­gy port­fo­lio.

On­corus, a five-year-old com­pa­ny, an­nounced Mon­day that it signed a 15-year lease to build an 88,000-square-foot GMP vi­ral im­munother­a­py clin­i­cal man­u­fac­tur­ing fa­cil­i­ty in An­dover, MA.

The com­pa­ny said in a press re­lease that it an­tic­i­pates the first phase of the fa­cil­i­ty will be fin­ished by the end of 2021 and will pri­or­i­tize process de­vel­op­ment and qual­i­ty con­trol. Once ful­ly op­er­a­tional — pro­ject­ed in 2023 — On­corus plans to have GMP mul­ti-prod­uct man­u­fac­tur­ing ca­pa­bil­i­ties avail­able to pro­duce clin­i­cal-grade vi­ral im­munother­a­pies for in­ves­ti­ga­tion­al new drug and clin­i­cal stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.